Vertex Pharmaceuticals Incorporated (VRTX) Earnings

Vertex Pharmaceuticals Incorporated

VRTX · NASDAQ-GS

Symbol: VRTX
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Exchange: NASDAQ-GS

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, congenital adrenal hyperplasia, ACTH-dependent Cushing's syndrome, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London.

Key Issues

Bullish view

Rising contributions from newer products, continued cystic-fibrosis growth and a near-term renal launch support Vertex’s diversification push and helped drive a higher 2026 sales outlook.

Bearish view

The cystic-fibrosis franchise remains the company’s main revenue engine, while newer products are still described as rising contributors rather than established businesses, leaving diversification execution-dependent.

Analyst Consensus

See all

Buy

27 analysts

$532

Current

—

Low

$580

Average

—

High

Average target implies +9.06% versus the current price.

Earnings History

BeatMissNo estimate

Dec 2026upcoming

Next quarter

Expected to report Feb 11, 2027 — estimated from last year’s reporting date.

Consensus is $4.08 EPS for Dec 2026 across 7 estimates, ranging $3.37 to $4.68.

VRTX Sep 2026

Reported Nov 2, 2026 · after the close

: 3.44%
: Pending

: $4.36
: $4.21
: —
: $3.44B

Reported results

: $3.44B; from $3.08B
: 84.71%; from 86.52%
: $712.90M; from $1.19B
: 20.72%; from 38.56%
: $653.60M; from $1.08B
: $2.56; from $4.20

Highlights

Revenue growth: Q3 revenue rose 12% year over year to $3.44 billion, with U.S. revenue up 10% to $2.17 billion and international revenue up 16% to $1.27 billion.
CF mix shift: CF sales increased 8% to $3.27 billion; ALYFTREK revenue reached $706 million, while TRIKAFTA/KAFTRIO fell 8% to $2.44 billion.
Newer launches: CASGEVY revenue was $99 million, up 30% sequentially, and JOURNAVX revenue was $58 million, up 18% sequentially; JOURNAVX prescriptions exceeded 750,000, up more than 40%.
EPS comparison: The supplied expectations data lists EPS of $4.21 against $4.36 consensus, a 3.44% miss. Vertex’s release reports diluted GAAP EPS of $2.56 and non-GAAP EPS of $4.76; the supplied materials do not reconcile the differing EPS bases.
Acquisition and expenses: Vertex closed its roughly $10 billion Crinetics acquisition on September 1; $502 million of related compensation and transaction costs weighed on GAAP results, while non-GAAP net income was $1.21 billion versus $1.24 billion a year earlier.
Guidance: Full-year revenue guidance rose to $13.15–$13.25 billion from $13.1–$13.2 billion, including expected PALSONIFY revenue of $40–$50 million. Non-GAAP combined R&D, acquired IPR&D and SG&A expense guidance increased to about $6.0 billion from $5.65–$5.75 billion.
Renal launch: Povetacicept’s FDA PDUFA date for IgAN is November 30, 2026; Vertex said its commercial team is ready for a potential launch.
Balance sheet: Cash, cash equivalents and marketable securities totaled $9.8 billion at quarter-end, after the Crinetics purchase and share repurchases, alongside $4.5 billion of term-loan borrowings.

Analysis

Vertex’s third quarter combined 12% revenue growth with a sharp decline in GAAP earnings as the company closed Crinetics and stepped up investment in launches and its pipeline. Revenue of $3.44 billion was up from $3.08 billion a year earlier and $3.33 billion in Q2. The supplied expectations data lists EPS of $4.21 versus $4.36 consensus, a 3.44% miss; however, the release reports diluted GAAP EPS of $2.56 and non-GAAP EPS of $4.76, so those figures are not directly comparable on the information provided. GAAP net income fell to $654 million from $1.08 billion a year ago and operating income to $713 million from $1.19 billion. Non-GAAP net income was $1.21 billion, modestly below $1.24 billion a year earlier.

The underlying commercial story was continued CF growth alongside scaling newer franchises: ALYFTREK reached $706 million, CASGEVY $99 million and JOURNAVX $58 million. The other defining event was Crinetics, which added PALSONIFY and endocrine programs but brought $502 million of acquisition-related costs and higher financing expense. Vertex raised revenue guidance by $50 million at the midpoint, largely reflecting PALSONIFY, while lifting non-GAAP expense guidance to about $6.0 billion. The November 30 povetacicept decision is the next near-term potential step in the company’s planned expansion into nephrology.

Commercial growth

CF portfolio: Revenue rose 8% to $3.27 billion. ALYFTREK contributed $706 million versus $247 million a year ago, while TRIKAFTA/KAFTRIO declined 8% to $2.44 billion. Vertex cited ALYFTREK uptake, new patient initiations, reimbursement gains and higher realized net prices; reimbursement reached 32 countries.
CASGEVY: Revenue was $99 million, up 30% from Q2 and nearly six times the $17 million recorded a year ago. Vertex reported more than 100 patient initiations for a fourth consecutive quarter and said approximately 200 infusions had been completed since launch. The U.S. approved use in children as young as 2 during the quarter.
JOURNAVX: Revenue reached $58 million, up 18% sequentially and nearly three times the year-ago quarter. More than 750,000 prescriptions were filled, up over 40% sequentially and more than fourfold year over year. Management said the patient-support program will remain in place into 2027; after it ends around midyear, it expects gross-to-net to settle near 50%–60%.
PALSONIFY: Vertex’s reported post-acquisition September contribution was $10 million. The company cited about 80% U.S. covered lives, roughly 500 prescribing endocrinologists and more than 40% brand share among patients starting or switching therapy.

Earnings and guidance

GAAP operating income was $713 million, down from $1.19 billion in Q3 2025 and $1.25 billion in Q2 2026. Combined GAAP R&D, acquired IPR&D and SG&A was about $2.2 billion versus $1.5 billion a year earlier; the non-GAAP total was $1.53 billion versus $1.28 billion. Vertex attributed the spending increase to commercial and pipeline investment, Crinetics-related costs and the JOURNAVX launch. Non-GAAP diluted EPS was $4.76 versus $4.80 a year ago. The supplied consensus EPS comparison is $4.21 against $4.36, but the materials do not explain its basis relative to the release’s GAAP and non-GAAP figures. Full-year revenue guidance increased by $50 million at the midpoint to $13.15–$13.25 billion, including expected PALSONIFY revenue of $40–$50 million. Non-GAAP combined expense guidance rose to approximately $6.0 billion, from $5.65–$5.75 billion, with Vertex citing Crinetics operating and integration costs.

Crinetics integration

Vertex completed its acquisition of Crinetics on September 1 for total equity value of about $10.0 billion, or $9.0 billion net of acquired cash and securities. The deal added PALSONIFY to the commercial portfolio and brought atumelnant, in Phase 3 for congenital adrenal hyperplasia, into the pipeline. Q3 included $502 million of acquisition-related compensation and transaction costs, including cash-settled unvested equity awards. The purchase also added substantial intangible assets, including a $3.0 billion PALSONIFY marketed-product asset and a $5.1 billion atumelnant in-process R&D asset. Management said the full-year non-GAAP expense outlook includes about $250 million of Crinetics operating and integration costs.

Renal pipeline

Povetacicept: The IgAN BLA is under priority FDA review with a November 30, 2026 PDUFA date. Vertex said its launch team is hired and trained and emphasized monthly at-home subcutaneous dosing by autoinjector. It plans to complete the trial’s two-year eGFR follow-up to support broader international submissions.
Inaxaplin: Vertex completed enrollment in the pivotal AMPLITUDE study and expects an interim analysis in early 2027 after the interim cohort reaches 48 weeks of treatment. In the separate AMPLIFIED study, reported week-13 reductions included UACR of 42.7% in the modest-proteinuria cohort and 17.3% in the type 2 diabetes cohort.
Other programs: Povetacicept’s Phase 3 pMN study is enrolling and dosing, with gMG proof-of-concept results expected in the first half of 2027. The company also completed enrollment in the Phase 2 ADPKD study of VX-407 and expects a readout in 2027.

Cash and financing

Cash, cash equivalents and marketable securities were $9.8 billion at September 30, down from $12.3 billion at year-end 2025. The decline primarily reflected the $9.1 billion net cash acquisition payment and share repurchases, partly offset by operating cash flow and $4.5 billion of term-loan proceeds. The loan bears variable-rate interest and is due in tranches of $1.0 billion in 2027, $1.0 billion in 2028 and $2.5 billion in 2029. Nine-month operating cash flow was $3.2 billion, compared with $3.1 billion in the prior-year period; Vertex repurchased $921 million of shares year to date.